Market Analysis by covering: S&P 500, Johnson & Johnson. Read 's Market Analysis on Investing.com
’s 16% gain and delivering the company’s strongest annual performance since 1995. Analysts expect fourth-quarter adjusted earnings of $2.42 per share on sales of $24.1 billion, while the company’s multiple myeloma portfolio, led by Darzalex and Tecvayli, is projected to generate as much as $25 billion in revenue by 2030.
Wall Street analysts believe the company is well-positioned to sustain revenue growth above 5%, supported by mid-single-digit expansion in Innovative Medicines through 2030 and a MedTech division that is increasingly focused on higher-growth segments. They also note that this outlook is further reinforced by accelerating Tremfya sales following its approval in inflammatory bowel disease .At the JPMorgan Healthcare Conference last week, CEO Joaquin Duato highlighted Johnson & Johnson’s growing multiple myeloma franchise—anchored by Darzalex and Tecvayli—which he said could generate about $25 billion in revenue by 2030, potentially a conservative estimate, citing what he called some of the most impressive multiple myeloma data to date from a Tecvayli–Darzalex combination. The company’s MedTech segment is also expanding, with worldwide operational sales up 5.6% year over year in the third quarter, driven by strength in electrophysiology and wound closure products, as well as contributions from acquired businesses Abiomed and Shockwave. Other products such as Xarelto and Simponi/Simponi Aria likely continued to grow, while rapid uptake of newer drugs—including Carvykti, Tecvayli, Talvey, Rybrevant, Lazcluze, Caplyta, and Spravato—also supported top-line gains. However, Stelara sales likely declined amid a wave of U.S. biosimilar launches in 2025 by Amgen, Teva, Samsung Bioepis/Sandoz, and others, with the loss of exclusivity reducing Innovative Medicines growth by 1,070 basis points in the third quarter and likely exerting an even greater drag in the fourth quarter as competition intensified. In a significant win for thousands of women suing Johnson & Johnson over claims that its talc-based baby powder caused ovarian cancer, court-appointed special master and retired U.S. District Judge Freda Wolfson recommended Tuesday that plaintiffs be allowed to present expert testimony supporting a causal link. The recommendation, affecting more than 67,500 federal cases consolidated in New Jersey, clears the way for the litigation to move toward a first federal trial potentially later this year, a key step in product liability suits where expert evidence often proves decisive.A Bernstein SocGen analyst reiterated a “market perform” rating on J&J and raised the price target to $208 from $193. Stifel raised its price target on Johnson & Johnson to $205 from $190 while maintaining a Hold rating, following the company’s $3.05 billion acquisition of oncology-focused Halda Therapeutics on Dec. 29. Stifel expects the deal to be dilutive to adjusted EPS by a total of $0.20, split evenly between 2025 and 2026 .Johnson & Johnson has staged a major rally after breaking out above the broad 174–142 consolidation range that persisted from March 2023 to August 2025.JNJ is advancing within a classic rising channel, repeatedly testing both its upper and lower bounds. Base case: A move up to 224–225 after earnings, followed by a gradual corrective pullback toward 206–205.JNJ Seasonality Chart: Since 2007, JNJ has ended January lower 55% of the time with an average decline of 0.1%, and February lower 53% of the time with an average decline of 0.2%.: AI-managed stock picks every month, with several picks that have already taken off in November and in the long term.Investing.com’s AI tool provides real-time market insights, advanced chart analysis, and personalized trading data to help traders make quick, data-driven decisions.: This feature aggregates 17 institutional-grade valuation models to cut through the noise and show you which stocks are overhyped, undervalued, or fairly priced.From debt ratios and profitability to analyst earnings revisions, you’ll have everything professional investors use to analyze stocks in one clean dashboard.Ali Merchant is a seasoned financial market professional with expertise in Technical Analysis, Treasury & Capital Markets, Trading, Sales, Research, Training, Fund & Relationship Management, Fintech, and Digitalization. He is a CMT charter holder and an active member of CMT Association, USA, American Association of Professional Technical Analysts, and CMT Association of Canada. He has worked on various roles and organizations in North America and the GCC, such as ABN Amro bank, Thomson Reuters, Refinitiv, MAK Allen & Day Capital Partners, and Bridge Information Systems.Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Greenland Crisis Triggers Market Repricing of Escalation RiskMarket Analysis by covering: Gold Spot US Dollar, Silver Spot US Dollar, Gold Futures, Silver Futures. Read 's Market Analysis on Investing.com
Read more »
US Dollar: PCE, GDP, and Political Risks Shape Outlook This WeekMarket Analysis by covering: US Dollar Index Futures. Read 's Market Analysis on Investing.com
Read more »
Bitcoin, Ethereum Pressured With Traders Unwilling to Bet on ’TACO’ BounceMarket Analysis by covering: Bitcoin US Dollar, Ethereum US Dollar. Read 's Market Analysis on Investing.com
Read more »
Gold and Silver: Greenland Tensions Reinforce the Strategic CaseMarket Analysis by covering: Gold Spot US Dollar, Silver Spot US Dollar, Gold Futures, Silver Futures. Read 's Market Analysis on Investing.com
Read more »
Super Micro Computer: 2 Analysts Turn Sour After 40% Fall—Can It Recover?Market Analysis by covering: Super Micro Computer Inc. Read 's Market Analysis on Investing.com
Read more »
Market Analysis and TrendsThis report provides an overview of current market dynamics and emerging trends.
Read more »